trial
as of 2026-07-01Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
NCTId NCT03271866
at a glance
— · Unknown
Enrollment 80 (estimated)
Sponsored by Central South University
Primary completion 2023-12-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Unknown
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-08-28
Primary completion
2023-12-31
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Central South UniversityLead Sponsor
Investigators
3
Tiannan Shao, M.D., Ph.D.Principal Investigator
Dongyu Kang, M.D.Principal Investigator
Renrong Wu, M.D., Ph.D.Study Chair
Sites
1 total
Changsha, China
Facts & assertions
4 sourced
Enrollment
80
Phase
NA
Primary Completion Date
2023-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator